Nat Immunol:itch抑制IL-17介导的肠炎机制

2016-07-18 佚名 生物谷

炎症反应是宿主抵抗微生物侵染以及组织损伤的保护性反应。然而,失去控制的炎症反应容易提高癌症病发与生长的风险。例如,患有IBD以及溃疡性肠炎的患者更加容易患大肠癌。因此,了解大肠炎症反应的机制对于理解大肠癌的发病原因十分重要。越来越多的证据表明IL-17在肠道炎症反应以及肿瘤生成中具有关键的作用,而IL-17在肠道中的特异性表达主要由Th17细胞、γδT细胞以及天然淋巴细胞完成。IL-17能够通过引

炎症反应是宿主抵抗微生物侵染以及组织损伤的保护性反应。然而,失去控制的炎症反应容易提高癌症病发与生长的风险。例如,患有IBD以及溃疡性肠炎的患者更加容易患大肠癌。因此,了解大肠炎症反应的机制对于理解大肠癌的发病原因十分重要。

越来越多的证据表明IL-17在肠道炎症反应以及肿瘤生成中具有关键的作用,而IL-17在肠道中的特异性表达主要由Th17细胞、γδT细胞以及天然淋巴细胞完成。IL-17能够通过引发下游多种细胞因子与趋化因子的表达,招募中性粒细胞与巨噬细胞到炎症部位造成组织损伤。

有研究表明肠道的微生物与局部的细胞因子环境共同促进了IL-23与IL-6的表达,之后进一步提高RORγt的活性,引起IL-17的表达。然而,细胞内部控制RORγt活性并调节IL-17表达的机制目前仍不清楚。

免疫细胞中信号蛋白的翻译后修饰过程主要是泛素化修饰。泛素化的完成需要一系列的酶促反应,包括E1、E2以及E3。Itch是一类泛素连接酶,它的失活伴随着多种器官的炎症紊乱。为了研究itch的缺失对大肠炎症以及大肠癌的发生具有怎样的作用,来自美国贝勒医学院的K Venuprasad课题组进行了深入研究,相关结果发表在最近一期的《natute immunology》杂志上。

首先作者比较了野生型小鼠与itch突变体小鼠的生理表型。结果显示,突变体小鼠相比野生型其肠炎的发生几率有了明显的提升,同时,突变体小鼠更加容易患大肠癌。进一步,作者发现突变体小鼠肠道的IL-17的表达量有了明显的上升。

为了研究Itch的缺失对IL-17的表达的影响是如何实现的,作者进行了体外实验,结果显示,Itch能够特异性地与细胞因子ROR-γt中的PPXY结构域相互作用。之后,作者发现itch与ROR-γt的结合能够导致后者的泛素化-K48修饰,进而导致ROR-γt的蛋白酶体降解。

之后,作者发现Itch缺失突变体小鼠中ROR-γt的活性确实发生了明显的提高,而且这一缺失突变能够促进小鼠肠道中IL-17的表达。进一步,作者证明itch的缺失引发的ROR-γt泛素化水平的下降能够促进肠道的炎症反应,这些结果共同证明了itch调节ROR-γt活性的作用。

原始出处

Mahesh Kathania, Prashant Khare, Minghui Zeng, Brandi Cantarel, Haiying Zhang, Hideki Ueno & K Venuprasad.tch inhibits IL-17-mediated colon inflammation and tumorigenesis by ROR-γt ubiquitination.Nat Immunol.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881196, encodeId=e7cc1881196d6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 14 00:22:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057829, encodeId=3559205e82900, content=<a href='/topic/show?id=02601010edf' target=_blank style='color:#2F92EE;'>#itch抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10107, encryptionId=02601010edf, topicName=itch抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Jun 18 22:22:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374407, encodeId=f47f13e440719, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508177, encodeId=77fe15081e734, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2017-01-14 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881196, encodeId=e7cc1881196d6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 14 00:22:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057829, encodeId=3559205e82900, content=<a href='/topic/show?id=02601010edf' target=_blank style='color:#2F92EE;'>#itch抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10107, encryptionId=02601010edf, topicName=itch抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Jun 18 22:22:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374407, encodeId=f47f13e440719, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508177, encodeId=77fe15081e734, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2017-06-18 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881196, encodeId=e7cc1881196d6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 14 00:22:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057829, encodeId=3559205e82900, content=<a href='/topic/show?id=02601010edf' target=_blank style='color:#2F92EE;'>#itch抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10107, encryptionId=02601010edf, topicName=itch抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Jun 18 22:22:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374407, encodeId=f47f13e440719, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508177, encodeId=77fe15081e734, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-20 fzwish20000
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881196, encodeId=e7cc1881196d6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 14 00:22:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057829, encodeId=3559205e82900, content=<a href='/topic/show?id=02601010edf' target=_blank style='color:#2F92EE;'>#itch抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10107, encryptionId=02601010edf, topicName=itch抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Jun 18 22:22:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374407, encodeId=f47f13e440719, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508177, encodeId=77fe15081e734, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed Jul 20 08:22:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-20 jjjiang0202

相关资讯

DDW 2013:低VD或增炎性肠病发作风险

  奥兰多——麻省总医院的Ashwin Ananthakrishnan医生在消化疾病周(DDW)上报告,维生素D可能有助于炎症性肠病(IBD)患者免于出现严重发作。   在中位接受8年随访的3,217例克罗恩病(CD)患者中,血浆25-羟基维生素D水平最低者接受手术和因IBD住院的风险,均为维生素D水平正常者的2倍左右。在溃疡性结肠炎(UC)患者中也观察到了相似关联。不仅如此,最初维生

Lancet:痛痛痛!罕见原因导致腹痛-案例报道

患者女,14岁,腹痛2天就诊,伴非胆汁性呕吐。查体:脸色苍白,弥漫性腹部压痛,肠鸣音减弱。辅助检查:血红蛋白 88 g/L,白细胞总数 3.6 × 109/L,血小板 96 × 109/L,红细胞沉降率(ESR) 54 mm/h;尿常规正、血和尿培养未见明显异常;其他血液检查、胸部平片、腹部B超、大便培养、显微镜和内镜检查无异常。腹部平片显示小肠大肠扩张,但没有肠梗阻或气腹。经验性静脉输注环丙沙星

Nat Med:CARD9通过调节肠道微生物代谢产物影响肠炎恢复能力

肠道微生物对于宿主的营养以及健康都具有重要的作用。这脆弱的生态平衡的打破会引起多种疾病,其中包括炎症性肠炎(IBD),CARD9是引发IBD的多种重要基因之一,它负责介导由模式识别受体激活后产生的胞内信号,包括NOD2,C type Lectin MAPK以及TLR信号通路等等。 CARD9能够通过IL-22调节肠炎的疾病调控,此前研究显示,CARD9缺失突变性小鼠更容易因肠道真菌感染引发肠炎